TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oryzon Genomics SA ( (ES:ORY) ) has provided an update.
Oryzon Genomics has submitted the protocol for its Phase III PORTICO-2 clinical trial to the FDA, aiming to evaluate the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). This trial seeks to address the unmet medical need of aggression in BPD, building on promising results from previous studies, and marks a significant advancement for Oryzon in the neuropsychiatry field.
The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.
More about Oryzon Genomics SA
Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in epigenetics. The company focuses on developing innovative therapies, particularly in the field of neuropsychiatry, using its expertise in epigenetic regulation.
YTD Price Performance: 94.29%
Average Trading Volume: 729,342
Technical Sentiment Signal: Buy
Current Market Cap: €210.8M
For a thorough assessment of ORY stock, go to TipRanks’ Stock Analysis page.